Anixa Biosciences (ANIX) Net Cash Flow (2010 - 2025)
Anixa Biosciences' (ANIX) quarterly Net Cash Flow came in at -$251000.0 in Q4 2025, down 645.65% YoY from $46000.0 in Q4 2024, and up 39.52% on a QoQ basis from -$415000.0 in Q3 2025.
Anixa Biosciences (ANIX) Net Cash Flow (2010 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of Net Cash Flow data on file, last reported at -$251000.0 in Q4 2025.
- Quarterly Net Cash Flow fell 645.65% year-over-year to -$251000.0 in Q4 2025, while the trailing twelve-month figure through Apr 2026 was $191000.0 (down 79.13% YoY) and the FY2025 annual result came in at -$27000.0, down 107.58% from the prior year.
- Net Cash Flow improved to -$251000.0 in Q4 2025, from -$415000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $15.7 million in Q2 2021 to a low of -$11.9 million in Q4 2022.
- A 5-year average of -$259000.0 and a median of -$234500.0 in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 724.03% — and 2025, when it jumped 28666.67%.
- Tracing ANIX's Net Cash Flow over 5 years: stood at $1.9 million in 2021, then tumbled by 724.03% to -$11.9 million in 2022, then soared by 80.81% to -$2.3 million in 2023, then surged by 102.01% to $46000.0 in 2024, then slumped by 645.65% to -$251000.0 in 2025.
- The last three Net Cash Flow figures came in at -$251000.0 (Q4 2025), -$415000.0 (Q3 2025), and $857000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 225.59 Mn |
| 10 | Anixa Biosciences | 123.96 Mn | 123.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | -251,000.00 |
| Oct 31, 2025 | -251,000.00 |
| Jul 31, 2025 | -415,000.00 |
| Jul 31, 2025 | -415,000.00 |
| Apr 30, 2025 | 857,000.00 |
| Apr 30, 2025 | 857,000.00 |
| Jan 31, 2025 | -218,000.00 |
| Jan 31, 2025 | -218,000.00 |
| Oct 31, 2024 | 46,000.00 |
| Oct 31, 2024 | 46,000.00 |
| Jul 31, 2024 | 230,000.00 |
| Jul 31, 2024 | 230,000.00 |
| Apr 30, 2024 | -3,000.00 |
| Apr 30, 2024 | -3,000.00 |
| Jan 31, 2024 | 83,000.00 |
| Jan 31, 2024 | 83,000.00 |
| Oct 31, 2023 | -2.28 Mn |
| Oct 31, 2023 | -2.28 Mn |
| Jul 31, 2023 | -2.42 Mn |
| Jul 31, 2023 | -2.42 Mn |